$CADL (CANDEL THERAPEUTICS) — 8-K: Candel adds regulatory and quality veteran Martine Zimmermann to board ahead of planned Q4 2026 BLA

Candel Therapeutics appointed Martine Zimmermann, PharmD, to its Board of Directors effective September 8, 2026. She brings more than 30 years of global regulatory affairs and quality expertise across all phases of drug development. The appointment comes as Candel prepares for the planned Biologics License Application submission for aglatimagene besadenovec in the fourth quarter of 2026.

Candel Therapeutics appointed Martine Zimmermann, PharmD, to its Board of Directors effective September 8, 2026. She brings more than 30 years of global regulatory affairs and quality expertise across